Evolus, Inc. (EOLS)
7.76
-0.81
(-9.45%)
USD |
NASDAQ |
Sep 10, 14:18
Evolus Shareholders Equity (Quarterly) : -30.90M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -30.90M |
| March 31, 2026 | -28.78M |
| December 31, 2025 | -23.11M |
| September 30, 2025 | -28.76M |
| June 30, 2025 | -18.65M |
| March 31, 2025 | -6.604M |
| December 31, 2024 | 5.522M |
| September 30, 2024 | 5.89M |
| June 30, 2024 | 19.31M |
| March 31, 2024 | 18.44M |
| December 31, 2023 | -20.69M |
| September 30, 2023 | -19.37M |
| June 30, 2023 | -6.963M |
| March 31, 2023 | 6.949M |
| December 31, 2022 | 18.50M |
| September 30, 2022 | 29.22M |
| June 30, 2022 | 46.86M |
| March 31, 2022 | 67.25M |
| December 31, 2021 | 81.88M |
| September 30, 2021 | 97.40M |
| Date | Value |
|---|---|
| June 30, 2021 | 106.14M |
| March 31, 2021 | 23.29M |
| December 31, 2020 | -72.96M |
| September 30, 2020 | 35.10M |
| June 30, 2020 | 43.60M |
| March 31, 2020 | 62.61M |
| December 31, 2019 | 79.46M |
| September 30, 2019 | 17.04M |
| June 30, 2019 | 41.18M |
| March 31, 2019 | 75.36M |
| December 31, 2018 | 84.38M |
| September 30, 2018 | 94.97M |
| June 30, 2018 | 37.94M |
| March 31, 2018 | 51.98M |
| December 31, 2017 | -75.54M |
| September 30, 2017 | -78.48M |
| June 30, 2017 | -67.01M |
| March 31, 2017 | |
| December 31, 2016 | -7.106M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 597.21M |
| Corcept Therapeutics, Inc. | 705.78M |
| Veru, Inc. | 28.38M |
| Johnson & Johnson | 84.97B |
| Eli Lilly & Co. | 33.88B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 248.02M |
| Total Liabilities (Quarterly) | 278.93M |
| Debt to Equity Ratio | -5.333 |
| Current Ratio | 1.697 |
| Net Debt Paydown Yield | -1.51% |